JP2004519454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004519454A5 JP2004519454A5 JP2002554677A JP2002554677A JP2004519454A5 JP 2004519454 A5 JP2004519454 A5 JP 2004519454A5 JP 2002554677 A JP2002554677 A JP 2002554677A JP 2002554677 A JP2002554677 A JP 2002554677A JP 2004519454 A5 JP2004519454 A5 JP 2004519454A5
- Authority
- JP
- Japan
- Prior art keywords
- dimethoxy
- dihydro
- quinazolin
- group
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 54
- -1 methylenedioxy Chemical group 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052757 nitrogen Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- NWWDMEBFEXNAQY-UHFFFAOYSA-N 2-(3-cyclohexyl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)C5CCCCC5)OC NWWDMEBFEXNAQY-UHFFFAOYSA-N 0.000 claims description 5
- NSMYFMQCZREYGB-UHFFFAOYSA-N 6,7-dimethoxy-2-(3-phenyl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)C5=CC=CC=C5)OC NSMYFMQCZREYGB-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- CFKFKGSYZNAKOS-UHFFFAOYSA-N 2-(6,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline-5-carbonitrile Chemical compound C1CC(C(=C(OC)C(OC)=C2)C#N)=C2CN1C1=NC(C=C(C(=C2)OC)OC)=C2C(=O)N1 CFKFKGSYZNAKOS-UHFFFAOYSA-N 0.000 claims description 3
- XCHMRCYMRVDBSW-UHFFFAOYSA-N 2-[4-(benzylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN=C2NCC1=CC=CC=C1 XCHMRCYMRVDBSW-UHFFFAOYSA-N 0.000 claims description 3
- BKTPWLOJLYJMJI-UHFFFAOYSA-N 6,7-dimethoxy-2-(4-piperidin-1-yl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN=C2N1CCCCC1 BKTPWLOJLYJMJI-UHFFFAOYSA-N 0.000 claims description 3
- JQOSCBFBHIQXRR-UHFFFAOYSA-N 6,7-dimethoxy-2-(5-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=CC=NC=C1 JQOSCBFBHIQXRR-UHFFFAOYSA-N 0.000 claims description 3
- ZSKWVHWKJVIBTJ-UHFFFAOYSA-N 6,7-dimethoxy-2-(5-pyrimidin-5-yl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=CN=CN=C1 ZSKWVHWKJVIBTJ-UHFFFAOYSA-N 0.000 claims description 3
- NONNATLFKKPMCH-UHFFFAOYSA-N 6,7-dimethoxy-2-(5-pyrrolidin-1-yl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2N1CCCC1 NONNATLFKKPMCH-UHFFFAOYSA-N 0.000 claims description 3
- VMAPZVYRBPLTBN-UHFFFAOYSA-N 6,7-dimethoxy-2-[4-[2-methoxyethyl(methyl)amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-1h-quinazolin-4-one Chemical compound COC1=C(OC)C=C2NC(N3CC=4N=CN=C(C=4CC3)N(C)CCOC)=NC(=O)C2=C1 VMAPZVYRBPLTBN-UHFFFAOYSA-N 0.000 claims description 3
- GABKFCIKDYWSQR-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-(1h-pyrrol-2-yl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=CC=CN1 GABKFCIKDYWSQR-UHFFFAOYSA-N 0.000 claims description 3
- NJVDRVLBZQASQR-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-(4-methoxyphenyl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC=CC2=C1CCN(C=1NC(=O)C3=CC(OC)=C(OC)C=C3N=1)C2 NJVDRVLBZQASQR-UHFFFAOYSA-N 0.000 claims description 3
- IXLKNTSCBQHVRZ-UHFFFAOYSA-N 6,7-dimethoxy-2-[7-(4-methoxyphenyl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C(CCN(C2)C=3NC(=O)C4=CC(OC)=C(OC)C=C4N=3)C2=C1 IXLKNTSCBQHVRZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- MYYKTZCWELANAY-UHFFFAOYSA-N 2-(3,4-dihydro-1h-pyrido[4,3-b][1,6]naphthyridin-2-yl)-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=NC=C2C=C(CN(C=3NC=4C=C(C(=CC=4C(=O)N=3)OC)OC)CC3)C3=NC2=C1 MYYKTZCWELANAY-UHFFFAOYSA-N 0.000 claims description 2
- NUVNTYDEDKGAPU-UHFFFAOYSA-N 2-[1-(4-chlorophenyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN2C1=CC=C(Cl)C=C1 NUVNTYDEDKGAPU-UHFFFAOYSA-N 0.000 claims description 2
- FSAGFYQBPWGVMA-UHFFFAOYSA-N 2-[5-(4,5-dihydro-1h-imidazol-2-ylamino)-3,4-dihydro-1h-isoquinolin-2-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2NC1=NCCN1 FSAGFYQBPWGVMA-UHFFFAOYSA-N 0.000 claims description 2
- ZZRHPMVACJGNBF-UHFFFAOYSA-N 3-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6,7-dimethoxy-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=C(OC)C=C2S(=O)(=O)NC(N3CCC=4C=C(C(=CC=4C3)OC)OC)=NC2=C1 ZZRHPMVACJGNBF-UHFFFAOYSA-N 0.000 claims description 2
- BZSCPRDBSKPCNT-UHFFFAOYSA-N 6,7-dimethoxy-2-(1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)-1h-quinazolin-4-one Chemical compound N1C2=CC=CC=C2C(CC2)=C1CN2C1=NC(C=C(C(=C2)OC)OC)=C2C(=O)N1 BZSCPRDBSKPCNT-UHFFFAOYSA-N 0.000 claims description 2
- NCHIHXQFKMPELD-UHFFFAOYSA-N 6,7-dimethoxy-2-(1-naphthalen-2-yl-6,7-dihydro-4h-imidazo[4,5-c]pyridin-5-yl)-1h-quinazolin-4-one Chemical compound C1=CC=CC2=CC(N3C=NC4=C3CCN(C4)C3=NC=4C=C(C(=CC=4C(=O)N3)OC)OC)=CC=C21 NCHIHXQFKMPELD-UHFFFAOYSA-N 0.000 claims description 2
- ZXJDRUCKZNIUDB-UHFFFAOYSA-N 6,7-dimethoxy-2-(1-phenyl-6,7-dihydro-4h-imidazo[4,5-c]pyridin-5-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN2C1=CC=CC=C1 ZXJDRUCKZNIUDB-UHFFFAOYSA-N 0.000 claims description 2
- XUGNZQMRYTVJRN-UHFFFAOYSA-N 6,7-dimethoxy-2-(4-morpholin-4-yl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN=C2N1CCOCC1 XUGNZQMRYTVJRN-UHFFFAOYSA-N 0.000 claims description 2
- UVPXAIPQNSGMNS-UHFFFAOYSA-N 6,7-dimethoxy-2-(5-morpholin-4-ylsulfonyl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2S(=O)(=O)N1CCOCC1 UVPXAIPQNSGMNS-UHFFFAOYSA-N 0.000 claims description 2
- FJFOFGNODBELRP-UHFFFAOYSA-N 6,7-dimethoxy-2-(5-pyridin-3-yl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=CC=CN=C1 FJFOFGNODBELRP-UHFFFAOYSA-N 0.000 claims description 2
- UAIZAGBMGMPSNL-UHFFFAOYSA-N 6,7-dimethoxy-2-(6-methoxy-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)-1h-quinazolin-4-one Chemical compound COC1=C(OC)C=C2C(=O)NC(N3CC=4NC5=CC=C(C=C5C=4CC3)OC)=NC2=C1 UAIZAGBMGMPSNL-UHFFFAOYSA-N 0.000 claims description 2
- FVYPHLUZMORLDY-UHFFFAOYSA-N 6,7-dimethoxy-2-[1-(3-methylphenyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-5-yl]-1h-quinazolin-4-one Chemical compound N=1C(=O)C=2C=C(OC)C(OC)=CC=2NC=1N(C1)CCC2=C1N=CN2C1=CC=CC(C)=C1 FVYPHLUZMORLDY-UHFFFAOYSA-N 0.000 claims description 2
- CPQOASVWAIUXGF-UHFFFAOYSA-N 6,7-dimethoxy-2-[1-(4-methoxyphenyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-5-yl]-1h-quinazolin-4-one Chemical compound C1=CC(OC)=CC=C1N1C(CCN(C2)C=3NC(=O)C4=CC(OC)=C(OC)C=C4N=3)=C2N=C1 CPQOASVWAIUXGF-UHFFFAOYSA-N 0.000 claims description 2
- PXSIQYGEMWYZAO-UHFFFAOYSA-N 6,7-dimethoxy-2-[4-(4-methylpiperazin-1-yl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN=C2N1CCN(C)CC1 PXSIQYGEMWYZAO-UHFFFAOYSA-N 0.000 claims description 2
- KGCAQIWQLMNEJR-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-(morpholin-4-ylmethyl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(CC1=CC=C2)CCC1=C2CN1CCOCC1 KGCAQIWQLMNEJR-UHFFFAOYSA-N 0.000 claims description 2
- LOSUHUKJOXFUHY-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-[(1-methylpyrrolidin-2-yl)amino]-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2NC1CCCN1C LOSUHUKJOXFUHY-UHFFFAOYSA-N 0.000 claims description 2
- JXCMPBSWEIGZIS-UHFFFAOYSA-N 6,7-dimethoxy-3-(4-morpholin-4-yl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl)-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN=C2N1CCOCC1 JXCMPBSWEIGZIS-UHFFFAOYSA-N 0.000 claims description 2
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 claims description 2
- 101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 claims description 2
- UCTSSAKPFOKZHT-UHFFFAOYSA-N n'-[2-(6,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-3,4-dihydro-1h-isoquinolin-5-yl]cyclobutanecarboximidamide Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2NC(=N)C1CCC1 UCTSSAKPFOKZHT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000003545 alkoxy group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000004414 alkyl thio group Chemical group 0.000 claims 12
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 8
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 8
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 8
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 claims 8
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 8
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 239000000674 adrenergic antagonist Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004971 nitroalkyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- XSXTYCBJTRYMFL-UHFFFAOYSA-N COC1=CC2=CNC(N3CC4=CC=CC(NC5=NCCC5)=C4CC3)N=C2C=C1OC Chemical compound COC1=CC2=CNC(N3CC4=CC=CC(NC5=NCCC5)=C4CC3)N=C2C=C1OC XSXTYCBJTRYMFL-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- CEIXWJHURKEBMQ-UHFFFAOYSA-N Heliamine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2 CEIXWJHURKEBMQ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- QLTVPNPZNQEUJY-UHFFFAOYSA-N 2-[5-(1h-imidazol-2-yl)-3,4-dihydro-1h-isoquinolin-2-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=NC=CN1 QLTVPNPZNQEUJY-UHFFFAOYSA-N 0.000 description 2
- DBOAGRILJPETJN-UHFFFAOYSA-N 2-chloro-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1=C(Cl)NC(=O)C2=C1C=C(OC)C(OC)=C2 DBOAGRILJPETJN-UHFFFAOYSA-N 0.000 description 2
- OSYBRIQODOIRJL-UHFFFAOYSA-N N-cyclohexyl-6-(6,7-dimethoxy-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-3-yl)-3,5,6,7-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-amine Chemical compound COC1=C(C=C2C(=C1)NC(=NS2(=O)=O)C3CN4CN(CC4=CN3)NC5CCCCC5)OC OSYBRIQODOIRJL-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- JXYOTTCEJSPHHY-UHFFFAOYSA-N 2-(3-butyl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound CCCCC1N=CC2=CNC(CN12)C3=NC4=CC(=C(C=C4C(=O)N3)OC)OC JXYOTTCEJSPHHY-UHFFFAOYSA-N 0.000 description 1
- PMZGXSOONNHUAF-UHFFFAOYSA-N 2-(3-tert-butyl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound CC(C)(C)C1N=CC2=CNC(CN12)C3=NC4=CC(=C(C=C4C(=O)N3)OC)OC PMZGXSOONNHUAF-UHFFFAOYSA-N 0.000 description 1
- YCLWUNHKRDNNND-UHFFFAOYSA-N 2-(5,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1CC2=C(OC)C=CC(OC)=C2CN1C(N1)=NC(=O)C2=C1C=C(OC)C(OC)=C2 YCLWUNHKRDNNND-UHFFFAOYSA-N 0.000 description 1
- CRXRGGSYKXAZGP-UHFFFAOYSA-N 2-(5-amino-3,4-dihydro-1h-isoquinolin-2-yl)-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1CC2=C(N)C=CC=C2CN1C1=NC(C=C(C(=C2)OC)OC)=C2C(=O)N1 CRXRGGSYKXAZGP-UHFFFAOYSA-N 0.000 description 1
- NKWQAHSDPPVNBU-UHFFFAOYSA-N 2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound COC1=C(OC)C=C2NC(N3CCC=4C=C(C(=CC=4C3)OC)OC)=NC(=O)C2=C1 NKWQAHSDPPVNBU-UHFFFAOYSA-N 0.000 description 1
- QVSJGOFGEHJQFM-UHFFFAOYSA-N 2-(7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-yl)-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1CC2=CC=3OCOC=3C=C2CN1C1=NC(C=C(C(=C2)OC)OC)=C2C(=O)N1 QVSJGOFGEHJQFM-UHFFFAOYSA-N 0.000 description 1
- LPWDEIBPEKPNAW-UHFFFAOYSA-N 2-(8-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1CC2=CC=CC(F)=C2CN1C1=NC(C=C(C(=C2)OC)OC)=C2C(=O)N1 LPWDEIBPEKPNAW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- AYTNQBBFZGEZRO-UHFFFAOYSA-N 2-[1-(3-chlorophenyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1N=CN2C1=CC=CC(Cl)=C1 AYTNQBBFZGEZRO-UHFFFAOYSA-N 0.000 description 1
- JZJLPLMQVDZABN-UHFFFAOYSA-N 2-[3-(2,2-dimethylpropyl)-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl]-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound CC(C)(C)CC1N=CC2=CNC(CN12)C3=NC4=CC(=C(C=C4C(=O)N3)OC)OC JZJLPLMQVDZABN-UHFFFAOYSA-N 0.000 description 1
- GJKILFRNRJGMPK-UHFFFAOYSA-N 2-[3-(azepan-1-yl)-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl]-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)N5CCCCCC5)OC GJKILFRNRJGMPK-UHFFFAOYSA-N 0.000 description 1
- FQZWTJCACWCJCJ-UHFFFAOYSA-N 2-[3-(benzylamino)-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl]-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)NCC5=CC=CC=C5)OC FQZWTJCACWCJCJ-UHFFFAOYSA-N 0.000 description 1
- OCFFADRRLHIKQH-UHFFFAOYSA-N 2-[3-(cyclohexylamino)-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl]-6,7-dimethoxy-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)NC5CCCCC5)OC OCFFADRRLHIKQH-UHFFFAOYSA-N 0.000 description 1
- ZCIHXRAPJKCVOS-UHFFFAOYSA-N 2-[5-(3,4-dihydro-2h-pyrrol-5-ylamino)-3,4-dihydro-1h-isoquinolin-2-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2NC1=NCCC1 ZCIHXRAPJKCVOS-UHFFFAOYSA-N 0.000 description 1
- FDEFJFNRGBFSMA-UHFFFAOYSA-N 2-[5-(4,5-dihydro-1h-imidazol-2-yl)-3,4-dihydro-1h-isoquinolin-2-yl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=NCCN1 FDEFJFNRGBFSMA-UHFFFAOYSA-N 0.000 description 1
- YBYKQBLKNLBKOI-UHFFFAOYSA-N 3-(3-cyclohexyl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-6,7-dimethoxy-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=C(C=C2C(=C1)NC(=NS2(=O)=O)C3CN4C(N=CC4=CN3)C5CCCCC5)OC YBYKQBLKNLBKOI-UHFFFAOYSA-N 0.000 description 1
- NWCUIOMZWJSZCN-UHFFFAOYSA-N 3-chloro-6,7-dimethoxy-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1=C(Cl)NS(=O)(=O)C2=C1C=C(OC)C(OC)=C2 NWCUIOMZWJSZCN-UHFFFAOYSA-N 0.000 description 1
- GXJHEWIXFLWVSE-UHFFFAOYSA-N 3-cyclohexylimidazo[1,5-a]pyrazine Chemical compound C1CCCCC1C1=NC=C2N1C=CN=C2 GXJHEWIXFLWVSE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JKYPKCLISGUJJW-UHFFFAOYSA-N 5-[2-(6,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-3,4-dihydro-1h-isoquinolin-5-yl]-1h-pyrimidine-2,4-dione Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C1=CNC(=O)NC1=O JKYPKCLISGUJJW-UHFFFAOYSA-N 0.000 description 1
- PUFOMTZHKGSUPV-UHFFFAOYSA-N 6,7-dimethoxy-2-(3-morpholin-4-yl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)N5CCOCC5)OC PUFOMTZHKGSUPV-UHFFFAOYSA-N 0.000 description 1
- UBHQOWFVCWZLLV-UHFFFAOYSA-N 6,7-dimethoxy-2-(3-piperidin-1-yl-3,5,6,7-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-3H-quinazolin-4-one Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)C3CN4C(N=CC4=CN3)N5CCCCC5)OC UBHQOWFVCWZLLV-UHFFFAOYSA-N 0.000 description 1
- CTNUPOBAFCJKLG-UHFFFAOYSA-N 6,7-dimethoxy-2-(5-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N=1C(=O)C=2C=C(OC)C(OC)=CC=2NC=1N(C1)CCC2=C1C=CC=C2N1CCOCC1 CTNUPOBAFCJKLG-UHFFFAOYSA-N 0.000 description 1
- YRYYAAIREZRJQD-UHFFFAOYSA-N 6,7-dimethoxy-2-(7-methylsulfanyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)-1h-quinazolin-4-one Chemical compound N1C2=CC(SC)=CC=C2C(CC2)=C1CN2C1=NC(C=C(C(=C2)OC)OC)=C2C(=O)N1 YRYYAAIREZRJQD-UHFFFAOYSA-N 0.000 description 1
- CJKFLQNZMIZRQC-UHFFFAOYSA-N 6,7-dimethoxy-2-(7-pyrrolidin-1-yl-3,4-dihydro-1h-isoquinolin-2-yl)-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(CC1=C2)CCC1=CC=C2N1CCCC1 CJKFLQNZMIZRQC-UHFFFAOYSA-N 0.000 description 1
- LMPCKBVSSIPJFI-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-(morpholine-4-carbonyl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C(=O)N1CCOCC1 LMPCKBVSSIPJFI-UHFFFAOYSA-N 0.000 description 1
- BQFXBMUMZGPRPD-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-(pyridin-2-ylamino)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound N=1C(=O)C=2C=C(OC)C(OC)=CC=2NC=1N(C1)CCC2=C1C=CC=C2NC1=CC=CC=N1 BQFXBMUMZGPRPD-UHFFFAOYSA-N 0.000 description 1
- VUGVSSXKXRAXIC-UHFFFAOYSA-N 6,7-dimethoxy-2-[5-(pyridine-3-carbonyl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1N(C1)CCC2=C1C=CC=C2C(=O)C1=CC=CN=C1 VUGVSSXKXRAXIC-UHFFFAOYSA-N 0.000 description 1
- WJAFOKZSRLZFOD-UHFFFAOYSA-N 6,7-dimethoxy-2-[8-(4-methoxyphenyl)-3,4-dihydro-1h-isoquinolin-2-yl]-1h-quinazolin-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC=CC2=C1CN(C=1NC(=O)C3=CC(OC)=C(OC)C=C3N=1)CC2 WJAFOKZSRLZFOD-UHFFFAOYSA-N 0.000 description 1
- HUMJBUFALBGGLM-UHFFFAOYSA-N C1CN(CC2=CC=CC=C21)C3=NC4=CC=CC(=C4C(=O)N3)C5=CN=CC=C5 Chemical compound C1CN(CC2=CC=CC=C21)C3=NC4=CC=CC(=C4C(=O)N3)C5=CN=CC=C5 HUMJBUFALBGGLM-UHFFFAOYSA-N 0.000 description 1
- MUSAISYGBVZPEU-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C(=O)NC(=N2)N3CCC4=C(C3)C=CC=C4CN5CCNCC5)OC Chemical compound COC1=C(C=C2C(=C1)C(=O)NC(=N2)N3CCC4=C(C3)C=CC=C4CN5CCNCC5)OC MUSAISYGBVZPEU-UHFFFAOYSA-N 0.000 description 1
- KVUSPGLRHXBJNC-UHFFFAOYSA-N N-cyclohexyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-amine Chemical compound C1CCC(CC1)NC2=NC=C3N2CCNC3 KVUSPGLRHXBJNC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25933701P | 2001-01-02 | 2001-01-02 | |
| US32526701P | 2001-09-27 | 2001-09-27 | |
| PCT/EP2001/014885 WO2002053558A1 (en) | 2001-01-02 | 2001-12-17 | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004519454A JP2004519454A (ja) | 2004-07-02 |
| JP2004519454A5 true JP2004519454A5 (https=) | 2005-05-26 |
| JP4031363B2 JP4031363B2 (ja) | 2008-01-09 |
Family
ID=26947245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002554677A Expired - Fee Related JP4031363B2 (ja) | 2001-01-02 | 2001-12-17 | α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1363899B1 (https=) |
| JP (1) | JP4031363B2 (https=) |
| KR (1) | KR100554813B1 (https=) |
| CN (1) | CN1237060C (https=) |
| AR (1) | AR035775A1 (https=) |
| AT (1) | ATE295362T1 (https=) |
| BR (1) | BR0116662A (https=) |
| CA (1) | CA2432578C (https=) |
| DE (1) | DE60110844T2 (https=) |
| ES (1) | ES2241891T3 (https=) |
| MX (1) | MXPA03005854A (https=) |
| PA (1) | PA8536001A1 (https=) |
| PE (1) | PE20020735A1 (https=) |
| UY (1) | UY27109A1 (https=) |
| WO (1) | WO2002053558A1 (https=) |
| ZA (1) | ZA200305038B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| JP2009513504A (ja) * | 2003-07-02 | 2009-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | ５−置換キナゾリノン誘導体 |
| WO2005005395A2 (en) | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
| FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| MX2007013595A (es) | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| JP4865724B2 (ja) * | 2005-11-24 | 2012-02-01 | キッセイ薬品工業株式会社 | 尿管結石症の治療用医薬 |
| CA2682162C (en) | 2007-04-02 | 2016-05-10 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| JP5498374B2 (ja) | 2007-04-17 | 2014-05-21 | エボテック・アーゲー | ２−シアノフェニル縮合複素環式化合物および組成物、ならびにその使用 |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| CN101417999A (zh) * | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| TWI421252B (zh) * | 2009-07-09 | 2014-01-01 | Irm Llc | 用於治療寄生蟲疾病之化合物及組合物 |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
| GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| RU2016126431A (ru) * | 2013-12-20 | 2018-01-25 | Лабораториос Дель Др. Эстеве С.А. | Конденсированные имидазолильные производные, их получение и применение в качестве лекарственных препаратов |
| JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| CN107434786B (zh) * | 2016-05-27 | 2025-11-18 | 广东东阳光药业股份有限公司 | 苯并咪唑化合物及其制备方法 |
| TWI791515B (zh) | 2017-04-24 | 2023-02-11 | 瑞士商諾華公司 | 治療療法 |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| HRP20230377T1 (hr) | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113164418A (zh) | 2018-12-05 | 2021-07-23 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN113727758A (zh) * | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| CN110950886A (zh) * | 2019-12-13 | 2020-04-03 | 苏州莱克施德药业有限公司 | 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2023057985A1 (en) * | 2021-10-08 | 2023-04-13 | Vrise Therapeutics, Inc. | Small molecules for treatement of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
| DE2757925A1 (de) * | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| WO2000055143A1 (en) * | 1999-03-17 | 2000-09-21 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
-
2001
- 2001-12-17 CA CA002432578A patent/CA2432578C/en not_active Expired - Fee Related
- 2001-12-17 WO PCT/EP2001/014885 patent/WO2002053558A1/en not_active Ceased
- 2001-12-17 MX MXPA03005854A patent/MXPA03005854A/es active IP Right Grant
- 2001-12-17 CN CNB018217133A patent/CN1237060C/zh not_active Expired - Fee Related
- 2001-12-17 JP JP2002554677A patent/JP4031363B2/ja not_active Expired - Fee Related
- 2001-12-17 ES ES01985417T patent/ES2241891T3/es not_active Expired - Lifetime
- 2001-12-17 DE DE60110844T patent/DE60110844T2/de not_active Expired - Fee Related
- 2001-12-17 BR BR0116662-0A patent/BR0116662A/pt not_active IP Right Cessation
- 2001-12-17 EP EP01985417A patent/EP1363899B1/en not_active Expired - Lifetime
- 2001-12-17 AT AT01985417T patent/ATE295362T1/de not_active IP Right Cessation
- 2001-12-17 KR KR1020037008921A patent/KR100554813B1/ko not_active Expired - Fee Related
- 2001-12-27 PA PA20018536001A patent/PA8536001A1/es unknown
- 2001-12-27 PE PE2001001308A patent/PE20020735A1/es not_active Application Discontinuation
- 2001-12-28 AR ARP010106092A patent/AR035775A1/es unknown
- 2001-12-28 UY UY27109A patent/UY27109A1/es not_active Application Discontinuation
-
2003
- 2003-06-28 ZA ZA200305038A patent/ZA200305038B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004519454A5 (https=) | ||
| JP4031363B2 (ja) | α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体 | |
| US8841299B2 (en) | Substituted pyrrolo[1,2-a]pyrazines as tankyrase inhibitors | |
| FI78296C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 2-substituerade 4-amino-6,7-dimetoxikinolinderivat. | |
| US7608622B2 (en) | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | |
| US6423716B1 (en) | Nitrogenous heterocyclic compounds | |
| JP2020519589A5 (https=) | ||
| JP2003530387A (ja) | キナゾリン化合物 | |
| RU2005117342A (ru) | Новые аминозамещенные производные дигидропиримидо [4,5d]-пиримидинона, их получение и применение в качестве фармацевтических средств | |
| HUP0400828A2 (hu) | Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| CA2450724A1 (en) | Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7 | |
| JP2004521892A (ja) | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 | |
| WO2008141843A1 (en) | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors | |
| AU2016425880B2 (en) | Naphthyridine compound, pharmaceutical composition and use thereof | |
| KR20140021629A (ko) | 단백질 키나제 저해제 | |
| MXPA05002743A (es) | Derivados arilpiperazina de benzodioxanos con heterociclos fusionados antidepresivos. | |
| US7091200B2 (en) | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | |
| KR20220090443A (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
| TWI428342B (zh) | 新穎二氫－唑并苯并二氮雜酮化合物、其製備方法及含其之醫藥組合物 | |
| WO1999043679A1 (en) | Imidazoquinazoline derivatives | |
| JP3024013B2 (ja) | フルオロエチルカンプトテシン誘導体 | |
| KR101917264B1 (ko) | 5-ht7 수용체 조절제로 작용하는 아제핀 유도체 | |
| AU780528B2 (en) | Fused azepinone cyclin dependent kinase inhibitors | |
| AU2002234586A1 (en) | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | |
| JP2023503875A (ja) | 新規なトリアゾロピリジン誘導体およびこれを含む薬学組成物 |